342 related items for PubMed ID: 16807619
1.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
2. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I, Chilvers M, Reiz RJ.
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[Abstract] [Full Text] [Related]
3. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS, McKay DW, Reiz RJ.
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[Abstract] [Full Text] [Related]
4. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA, Punzi CF.
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[Abstract] [Full Text] [Related]
5. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
[Abstract] [Full Text] [Related]
6. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B.
Curr Med Res Opin; 2001 Aug; 17(1):8-17. PubMed ID: 11464450
[Abstract] [Full Text] [Related]
7. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of the ESTEPP Study.
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[Abstract] [Full Text] [Related]
8. Effectiveness of eprosartan in diabetic hypertensive patients.
Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
[Abstract] [Full Text] [Related]
9. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
Labiós M, Martínez M, Gabriel F, Guiral V, Munoz A, Aznar J.
Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
[Abstract] [Full Text] [Related]
10. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
[Abstract] [Full Text] [Related]
11. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.
Breeze E, Rake EC, Donoghue MD, Fletcher AE.
J Hum Hypertens; 2001 Dec; 15(12):857-62. PubMed ID: 11773988
[Abstract] [Full Text] [Related]
12. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV, Rudmann MA.
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[Abstract] [Full Text] [Related]
13. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Pathak A, Hanon O, Negre-Pages L, Sevenier F, OSCAR investigators.
Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
[Abstract] [Full Text] [Related]
14. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A, Verboom CN, Jäger B.
J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
[Abstract] [Full Text] [Related]
15. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
[Abstract] [Full Text] [Related]
16. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
Rake EC, Breeze E, Fletcher AE.
J Hum Hypertens; 2001 Dec 17; 15(12):863-7. PubMed ID: 11773989
[Abstract] [Full Text] [Related]
17.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
18. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
Drugs Exp Clin Res; 2004 Dec 17; 30(3):125-32. PubMed ID: 15366789
[Abstract] [Full Text] [Related]
19. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ.
J Am Soc Nephrol; 2004 Nov 17; 15(11):2902-7. PubMed ID: 15504943
[Abstract] [Full Text] [Related]
20. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH, Burgess ED, Assouline L, Vanjaka A.
Clin Ther; 2007 Feb 17; 29(2):305-15. PubMed ID: 17472822
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
